The results of a new clinical trial have shown the safety and efficacy of the interoperable Artificial Pancreas System smartphone app (iAPS), which can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms. The app runs on an unlocked smartphone.

Overview of the iAPS system components: smartphone running the client app, Dexcom G5/G6 CGM, and Tandem or Insulet insulin pumps. (Credit: Diabetes Technology & Therapeutics)

The Artificial Pancreas phase, compared to the Sensor-Augmented Pump phase, trended toward improved time in the target glucose range (70–180 mg/dL) and yielded a statistically significant reduction in time below 70 mg/dL.

The iAPS provides wireless integration with Dexcom G5 and G6 CGM and two different insulin pumps: a modified Tandem t:slim™ insulin pump (the Tandem t:AP pump) and an OmniPod® insulin pump with a modified Personal Diabetes Manager. The modifications made to each pump system by the different vendors allow for Bluetooth Low Energy (BLE) communication with a smartphone.

For more information, visit here .